Lechleiter vaults to No. 2 position at Lilly

Share this article:
Eli Lilly has promoted John Lechleiter, its executive vice president of pharmaceutical operations, to president and chief operating officer. He also has been made a member of the board of directors.
As such, Lechleiter will handle much of the company's daily operations.
"This new leadership structure, which provides a balance of both strategic and operational focus, is right for this time of rapid change," Lilly Chief Executive Sidney Taurel said in a statement.
Indeed, the timing could be right for Lechleiter, who earned his Ph.D. in organic chemistry from Harvard and joined Lilly in 1979 as a senior research chemist, to effect positive changes in at least one of the firm's big franchises.
U.S. sales of schizophrenia drug Zyprexa (olanzapine) decreased 21 percent in the second quarter, to $549.3 million, due to competition from other drugs. But Zyprexa fared well in a new study appearing in the New England Journal of Medicine, which showed olanzapine was slightly better than other atypical antipsychotic drugs and one generic, although it also was associated with significant weight gain.
Lechleiter has held various roles in pharmaceutical product development, project management and regulatory affairs at the Indianapolis drug maker. He assumed the role of executive vice president of pharmaceutical operations in 2004 and then took on responsibility for U.S. operations that same year.
In addition, Lechleiter's new post could make him a likely candidate to succeed Taurel as CEO, noted Forbes.com. Taurel spent three years as president and chief operating officer, and eight as a board member, before becoming Lilly chief executive in 1999.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...